Gonadotropin-releasing hormone agonist triggering with concomitant administration of low doses of human chorionic gonadotropin or a freeze-all strategy in high responders

References

1. ↵
   1. Whelan JG,
   2. Vlahos NF

   (2000) The ovarian hyperstimulation syndrome. Fertil Steril 73:883–896.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. García-Velasco JA,
   2. Zúñiga A,
   3. Pacheco A,
   4. Gómez R,
   5. Simón C,
   6. Remohí J

   (2004) Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod Oxf Engl 19:1530–1538.

   OpenUrl
3. ↵
   1. Al-Innay HG,
   2. Youssef MA,
   3. Aboulghar M,
   4. Broekmans F,
   5. Sterrenburg M,
   6. Smit J,
   7. et al.

   (2011) Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 11:CD001750.

   OpenUrl
4. ↵
   1. Lambalk CB,
   2. Leader A,
   3. Olivennes F,
   4. Fluker MR,
   5. Andersen AN,
   6. Ingerslev J,
   7. et al.

   (2006) Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinisation in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. Hum Reprod 21:632–639.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Humaidan P,
   2. Bredkjaer HE,
   3. Bungum L,
   4. Bungum M,
   5. Grøndahl ML,
   6. Westergaard L,
   7. et al.

   (2005) GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 20:1213–1220.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Beckers NG,
   2. Macklon NS,
   3. Eijkemans MJ,
   4. Ludwig M,
   5. Felberbaum RE,
   6. Diedrich K,
   7. et al.

   (2003) Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist co-treatment. J Clin Endocrinol Metab 88:4186–4192.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Orvieto R,
   2. Rabinson J,
   3. Meltzer S,
   4. Zohav E,
   5. Anteby E,
   6. Homburg R

   (2006) Substituting HCG with GnRH agonist to trigger final follicular maturation - a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 13:198–201.

   OpenUrlPubMedWeb of Science
8. ↵
   1. Griesinger G,
   2. Kolibianakis EM,
   3. Papanikolaou EG,
   4. Diedrich K,
   5. Van Steirteghem A,
   6. Devroey P,
   7. et al.

   (2007) Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil Steril 88:616–621.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Bodri D,
   2. Guillén JJ,
   3. Trullenque M,
   4. Schwenn K,
   5. Esteve C,
   6. Coll O

   (2010) Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. Fertil Steril 93:2418–2420.

   OpenUrlCrossRefPubMed
10. ↵
    1. Engmann L,
    2. DiLuigi A,
    3. Schmidt D,
    4. Nulsen J,
    5. Maier D,
    6. Benadiva C

    (2008) The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 89:84–91.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Shapiro BS,
    2. Daneshmand ST,
    3. Garner FC,
    4. Aguirre M,
    5. Hudson C

    (2011) Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 95:2715–2717.

    OpenUrlCrossRefPubMed
12. ↵
    1. Humaidan P,
    2. Bungum L,
    3. Bungum M,
    4. Yding Andersen C

    (2006) Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 13:173–178.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Radesic B,
    2. Tremellen K

    (2011) Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod 26:3437–3442.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Datta AK,
    2. Eapen A,
    3. Birch H,
    4. Kurinchi-Selvan A,
    5. Lockwood G

    (2014) Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders. Reprod Biomed Online 29:552–558.

    OpenUrl
15. ↵
    1. Iliodromiti S,
    2. Blockeel C,
    3. Tremellen KP,
    4. Fleming R,
    5. Tournaye H,
    6. Humaidan P,
    7. et al.

    (2013) Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicenter study. Hum Reprod 28:2529–2536.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Garcia-Velasco JA

    (2012) Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertil Steril 97:527–528.

    OpenUrlCrossRefPubMed
17. ↵
    1. Griesinger G,
    2. Schultz L,
    3. Bauer T,
    4. Broessner A,
    5. Frambach T,
    6. Kissler S

    (2011) Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril 95:2029–2033.

    OpenUrlCrossRefPubMed
18. ↵
    1. Devroey P,
    2. Polyzos NP,
    3. Blockeel C

    (2011) An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 26:2593–2597.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    1. Van Steirteghem AC,
    2. Nagy Z,
    3. Joris H,
    4. Liu J,
    5. Staessen C,
    6. Smitz J,
    7. et al.

    (1993) High fertilization and implantation rates after intracytoplasmic sperm injection. Hum Reprod 8:1061–1066.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Ku-wayama M

    (2007) Highly efficient vitrification for cryopreservation of human oocytes and embryos: the Cryotop method. Theriogenology 67:73–80.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    1. Golan A,
    2. Ron-el R,
    3. Herman A,
    4. Soffer Y,
    5. Weinraub Z,
    6. Caspi E

    (1989) Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 44:430–440.

    OpenUrlCrossRefPubMed
22. ↵
    1. Farhi J,
    2. Ben-Haroush A,
    3. Andrawus N,
    4. Pinkas H,
    5. Sapir O,
    6. Fisch B,
    7. et al.

    (2010) High serum oestradiol concentrations in IVF cycles increase the risk of pregnancy complications related to abnormal placentation. Reprod Biomed Online 21:331–337.

    OpenUrlCrossRefPubMed
23. ↵
    1. Roque M,
    2. Lattes K,
    3. Serra S,
    4. Solà I,
    5. Geber S,
    6. Carreras R,
    7. et al.

    (2013) Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril 99:156–162.

    OpenUrlCrossRefPubMed
24. 1. Youssef MA,
    2. Van der Veen F,
    3. Al-Inany HG,
    4. Mochtar MH,
    5. Griesinger G,
    6. Aboulfoutoh I,
    7. et al.

    (2016) The updated Cochrane review 2014 on GnRH agonist trigger: an indispensable piece of information for the clinician. Reprod Biomed Online 32:259–260.

    OpenUrl
25. ↵
    1. Kummer NE,
    2. Feinn RS,
    3. Griffin DW,
    4. Nulsen JC,
    5. Benadiva CA,
    6. Engmann LL

    (2013) Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger. Hum Reprod 28:152–159.

    OpenUrlCrossRefPubMed
26. ↵
    1. Itskovitz-Eldor J,
    2. Kol S,
    3. Mannaerts B

    (2000) Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 15:1965–1968.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    1. Engmann L,
    2. Siano L,
    3. Schmidt D,
    4. Nulsen J,
    5. Maier D,
    6. Benadiva C

    (2006) GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod Biomed Online 13:639–644.

    OpenUrlPubMedWeb of Science
28. ↵
    1. Haas J,
    2. Ophir L,
    3. Barzilay E,
    4. Yerushalmi GM,
    5. Yung Y,
    6. Kedem A,
    7. et al.

    (2014) GnRH agonist vs. hCG for triggering of ovulation--differential effects on gene expression in human granulosa cells. PLoS One 6(9):e90359.

    OpenUrl
29. ↵
    1. Seyhan A,
    2. Ata B,
    3. Polat M,
    4. Son WY,
    5. Yarali H,
    6. Dahan MH

    (2013) Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 28:2522–2528.

    OpenUrlCrossRefPubMedWeb of Science
30. ↵
    1. Fatemi HM,
    2. Popovic-Todorovic B,
    3. Humaidan P,
    4. Kol S,
    5. Banker M,
    6. Devroey P,
    7. et al.

    (2014) Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril 101:1008–1011.

    OpenUrlCrossRefPubMed
31. ↵
    1. Gurbuz AS,
    2. Gode F,
    3. Ozcimen N,
    4. Isik AZ

    (2014) Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online 29:541–544.

    OpenUrlCrossRefPubMed